Abstract
Aim/Hypothesis Five subgroups were described in European diabetes patients using a data driven machine learning approach on commonly measured variables. We aimed to test the applicability of this phenotyping in Indian young-onset type 2 diabetes patients.
Methods We applied the European derived centroids to the Indian type 2 diabetes patients diagnosed before 45 years of age from the WellGen (n = 1612) cohort. We also applied de novo k-means clustering to the WellGen cohort to validate the subgroups. We then compared clinical and metabolic-endocrine characteristics and the complication rates between the subgroups. We also compared characteristics of the WellGen subgroups with those of two young European cohorts ANDIS (n= 962) and DIREVA (n=420). Subgroups were also assessed in two other Indian cohorts, Ahmedabad (n = 187) and PHENOEINDY-2 (n = 205).
Results Both Indian and European young type 2 diabetes patients were predominantly classified into severely insulin-deficient (SIDD) and mild obesity-related (MOD) subgroups, while the severely insulin-resistant (SIRD) and mild age-related (MARD) subgroups were rare. In WellGen, SIDD (53%) was more common than MOD (38%), contrary to figures in Europeans (Swedish: 26% vs 68%, Finnish: 24% vs 71% respectively). A higher proportion of SIDD compared to MOD was also seen in Ahmedabad (57% vs 33%) and in PHENOEINDY-2 (67% vs 23%). Both in Indians and Europeans, the SIDD subgroup was characterized by insulin deficiency and hyperglycemia, MOD by obesity, SIRD by severe insulin resistance and MARD by mild metabolic-endocrine disturbances. In WellGen, nephropathy and retinopathy were more prevalent in SIDD compared to MOD while the latter had higher prevalence of neuropathy.
Conclusions /Interpretation Our data identified insulin deficiency as the major driver of type 2 diabetes in young Indians, unlike in young European patients in whom obesity and insulin resistance predominate. Our results provide useful clues to pathophysiological mechanisms and susceptibility to complications in young Indian type 2 diabetes, and suggest a need to review management strategies.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by grants from the Indo-Swedish joint network grant from the Swedish Research Council and the Department of Science and Technology, India (Dnr/Reg. nr: 2015-06722) to RBP and C/3019/IFD/2018-2019 to CSY, Wellcome Trust to CSY, Swedish Research Council (2017-02688), Diabetes Wellness Sweden (25-420 PG) and the Novo Nordisk Foundation (NNF18OC0034408) to EA, Swedish Research Foundation (2015-2558) to LG, the Swedish Heart and Lung Foundation, the Crafoord Foundation, the Swedish Diabetes Foundation and the Albert Påhlsson Research Foundation. The DIREVA Study is supported by the Vasa Hospital district, The Academy of Finland (grants no. 263401, 267882, 312063 to LG, 312072 to TT), University of Helsinki, Ollqvist Foundation, Finnish Diabetes Research Foundation, Helsinki University Central Hospital Research Foundation, Jakobstadsnejdens heart foundation to AK. CSY was a visiting Professor to Danish Diabetes Academy (supported by Novo Nordisk Foundation) and Southern University of Denmark during 2016-1019.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All studies were approved by the local/regional Institutional Ethics Committees. The WellGen study was approved by the Institutional Ethics Committee, King Edward Memorial Hospital Research Centre (KEM/HRC/Dir.Off/977, 2004; KEMHRC/LGF/EC/1608A, 2017). The Ahmedabad study was approved by the regional Ethics Committee in Ahmedabad (Rudraksha/Dir.off/380015, 2020). The PHENOEINDY2 study was approved by Institutional Ethics Committee, Assam Medical College (AMC/EC/932, 2007). The ANDIS study was approved by regional ethics review committee in Scania (584/2006 and 2012/676). The DIREVA study was approved by the ethics committee in Vaasa (6/2007). All subjects gave written informed consent.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data is available with Prof C S Yajnik and Dr Rashmi Prasad for sharing to confirm our findings and for additional analyses by applying to the corresponding author with a 200-word plan of analysis. Data sharing is subject to local/regional Institutional Ethics Committees approval and Government of India Health Ministry advisory committee permission.
